Department of Pathology, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA.
Department of Biochemistry and Molecular Genetics, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA.
Int J Mol Sci. 2021 Dec 20;22(24):13635. doi: 10.3390/ijms222413635.
Glioblastoma (GBM) is the most common adult neural malignancy and the deadliest. The standard of care is optimal, safe, cytoreductive surgery followed by combined radiation therapy and alkylating chemotherapy with temozolomide. Recurrence is common and therapeutic options in the recurrent setting are limited. The dismal prognosis of GBM has led to novel treatments being a serious roadblock in the field, with most new treatments failing to show efficacy. Targeted therapies have shown some success in many cancers, but GBM remains one of the most difficult to treat, especially in recurrence. New chemotherapeutic directions need to be explored, possibly expanding the targeted chemotherapy spectrum in previously unforeseen ways. In this perspective paper, we will explain why AVIL, an actin-binding protein recently found to be overexpressed in GBM and a driving force for GBM, could prove versatile in the fight against cancer. By looking at AVIL and its potential to regulate FOXM1 and LIN28B, we will be able to highlight a way to improve outcomes for GBM patients who normally have very little hope.
胶质母细胞瘤（GBM）是最常见的成人神经恶性肿瘤，也是最致命的肿瘤。目前的标准治疗方法是在安全的前提下，尽可能地进行手术切除，然后进行放疗和烷化剂化疗联合替莫唑胺治疗。肿瘤复发很常见，在复发的情况下，治疗选择有限。GBM 的预后较差，这导致新的治疗方法成为该领域的一个严重障碍，大多数新的治疗方法都未能显示出疗效。靶向治疗在许多癌症中取得了一定的成功，但 GBM 仍然是最难治疗的癌症之一，尤其是在复发的情况下。需要探索新的化疗方向，可能以以前未预见的方式扩大靶向化疗的范围。在这篇观点文章中，我们将解释为什么 AVIL，一种最近在 GBM 中发现过度表达的肌动蛋白结合蛋白，并且是 GBM 的驱动因素，可能在对抗癌症方面具有多功能性。通过研究 AVIL 及其调节 FOXM1 和 LIN28B 的潜力，我们将能够为通常希望渺茫的 GBM 患者提供改善预后的方法。
